BioIncept is a Pioneer in Tissue Regeneration and cellular repair

• We have shown to regulate and stimulate self-renewal of damaged tissue across body systems, without the common challenges afflicted with cellular therapies
• Key platform highlights include, amongst others, neuronal re-myelination (multiple sclerosis models, Nature); restoration of gastro-intestinal crypt architecture (radiation injury models, Oncotarget); reversal of muscle fibrosis (Duchenne muscular dystrophy models, Cell Death & Disease)
• The ability to therapeutically recover and restore health of diseased tissue presents significant opportunities in regenerative therapeutics
• Our team is hand-picked from seasoned veterans across the drug development value chain
• Our lead product candidate is uniquely positioned to become a solution for patients on the back of in-vivo proof-of-concept data
• We have shown proof-of-concept in animal models of several pathologies afflicted with Long Covid
• Positive study results may be transformative for Long Covid and confirm our strategic platform potential in other disease areas